2017
DOI: 10.1021/acs.molpharmaceut.6b01172
|View full text |Cite
|
Sign up to set email alerts
|

Spectroscopic Investigation of the Formation and Disruption of Hydrogen Bonds in Pharmaceutical Semicrystalline Dispersions

Abstract: We recently found that indomethacin (IMC) can effectively act as a powerful crystallization inhibitor for polyethylene glycol 6000 (PEG) despite the fact that the absence of interactions between the drug and the carrier in the solid state was reported in the literature. However, in the present study, we investigate the possibility of drug-carrier interactions in the liquid state to explain the polymer crystallization inhibition effect of IMC. We also aim to discover other potential PEG crystallization inhibito… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

3
26
0

Year Published

2018
2018
2024
2024

Publication Types

Select...
6
1
1

Relationship

0
8

Authors

Journals

citations
Cited by 21 publications
(29 citation statements)
references
References 61 publications
3
26
0
Order By: Relevance
“…In pharmaceutical semicrystalline SD, the hydrophilic carrier contains both crystalline and amorphous domains and the API can be amorphous, crystalline, or partially crystalline [ 1 ]. These systems have attracted extensive attention due to their complexity in terms of physical state, as both the carrier and the API can undergo crystalline phase modifications during production of the solid dispersion and/or during storage [ 1 , 2 ]; on one hand, the hydrophilic carrier can accelerate, slow down, or have no effect on the crystallization of the drug [ 3 , 4 ]; on the other hand, the drug can affect the crystallization of the carrier [ 2 ].…”
Section: Introductionmentioning
confidence: 99%
“…In pharmaceutical semicrystalline SD, the hydrophilic carrier contains both crystalline and amorphous domains and the API can be amorphous, crystalline, or partially crystalline [ 1 ]. These systems have attracted extensive attention due to their complexity in terms of physical state, as both the carrier and the API can undergo crystalline phase modifications during production of the solid dispersion and/or during storage [ 1 , 2 ]; on one hand, the hydrophilic carrier can accelerate, slow down, or have no effect on the crystallization of the drug [ 3 , 4 ]; on the other hand, the drug can affect the crystallization of the carrier [ 2 ].…”
Section: Introductionmentioning
confidence: 99%
“…The single glass transition indicated the phase homogeneity of IMC and PVOH in IMC/PVOH HME (3 : 7) on a scale of several tens of nanometer. 30) Moreover, the IMC/PVOH HMEs (3 : 7) showed endothermic peaks in the range of 150-200°C. The endothermic peak would be derived from the melting of crystalline phase of PVOH, which was observed in the PXRD patterns (Fig.…”
Section: Resultsmentioning
confidence: 97%
“…60 nm. Molecular modeling (Figure ) based on SAXS and XRD data reveals that in the best fit model, the long PEG chains are folded five times (Figure a) . The interactions between PDI cores and between perfluoroalkyl chains are responsible for the formation of an ordered lamellar phase (Figure b,c).…”
Section: Figurementioning
confidence: 99%